KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBT (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of EBT data on record, last reported at $90.4 million in Q4 2025.

  • For Q4 2025, EBT fell 76.83% year-over-year to $90.4 million; the TTM value through Dec 2025 reached $1.3 billion, down 17.78%, while the annual FY2025 figure was $1.3 billion, 17.78% down from the prior year.
  • EBT reached $90.4 million in Q4 2025 per EW's latest filing, down from $348.4 million in the prior quarter.
  • Across five years, EBT topped out at $545.5 million in Q2 2021 and bottomed at $90.4 million in Q4 2025.
  • Average EBT over 5 years is $370.7 million, with a median of $389.7 million recorded in 2021.
  • Peak YoY movement for EBT: skyrocketed 424.32% in 2021, then plummeted 76.83% in 2025.
  • A 5-year view of EBT shows it stood at $376.3 million in 2021, then tumbled by 43.82% to $211.4 million in 2022, then grew by 17.17% to $247.7 million in 2023, then surged by 57.49% to $390.1 million in 2024, then tumbled by 76.83% to $90.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $90.4 million in Q4 2025, $348.4 million in Q3 2025, and $400.2 million in Q2 2025.